• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Introduction to Compound with CAS No. 25682-47-7 and Product Name: 8,11-diazatricyclo4.3.3.0,1,6dodecane

The compound with the CAS number 25682-47-7 and the product name 8,11-diazatricyclo4.3.3.0,1,6dodecane represents a significant advancement in the field of organic chemistry and pharmaceutical research. This compound belongs to a class of tricyclic amines, which have garnered considerable attention due to their unique structural properties and potential applications in medicinal chemistry.

The molecular structure of 8,11-diazatricyclo4.3.3.0,1,6dodecane features a tricyclic framework with two nitrogen atoms incorporated into the ring system. This configuration imparts distinct electronic and steric properties to the molecule, making it a versatile scaffold for drug design. The presence of nitrogen atoms in the ring enhances the compound's ability to interact with biological targets, particularly enzymes and receptors involved in various metabolic pathways.

Recent studies have highlighted the importance of tricyclic compounds in the development of novel therapeutic agents. The rigid three-dimensional structure of these molecules often provides improved binding affinity and selectivity compared to linear or cyclic analogs. This characteristic has made tricyclic amines particularly attractive for targeting proteins that exhibit conformational flexibility or require precise spatial orientation for effective interaction.

In particular, 8,11-diazatricyclo4.3.3.0,1,6dodecane has been investigated for its potential role in modulating enzyme activity associated with inflammatory responses and neurodegenerative diseases. Preliminary research suggests that this compound can interact with specific enzymatic sites, potentially inhibiting pathways that contribute to disease progression. The nitrogen-rich structure allows for hydrogen bonding and hydrophobic interactions, which are crucial for establishing stable binding with biological targets.

The synthesis of 8,11-diazatricyclo4.3.3.0,1,6dodecane involves complex organic transformations that require precise control over reaction conditions to achieve high yields and purity. Advanced synthetic methodologies, including transition metal-catalyzed cyclizations and ring-closing metathesis reactions, have been employed to construct the tricyclic core efficiently. These synthetic strategies not only enhance the accessibility of the compound but also provide opportunities for structural modifications to optimize its pharmacological properties.

One of the most compelling aspects of 8,11-diazatricyclo4.3.3.0,1,6dodecane is its potential as a lead compound for further drug development. By leveraging computational chemistry techniques such as molecular docking and quantum mechanical calculations, researchers can predict how this molecule might interact with various biological targets at an atomic level. This approach enables the identification of key binding residues and functional groups that can be modified to improve potency and reduce side effects.

Current research is also exploring the pharmacokinetic profile of 8,11-diazatricyclo4.3.3.0,1,6dodecane, aiming to understand its absorption, distribution, metabolism, and excretion (ADME) properties. These studies are crucial for assessing the compound's bioavailability and determining optimal dosing regimens for therapeutic applications. Additionally, toxicological evaluations are being conducted to ensure safety and identify any potential liabilities before moving into clinical trials.

The versatility of 8,11-diazatricyclo4.3.3.0,1,6dodecane extends beyond its initial applications in inflammation and neurodegeneration; it also shows promise in addressing other therapeutic areas such as oncology and infectious diseases. By modifying specific functional groups within the tricyclic framework or exploring derivatives with different substituents, scientists can tailor the compound's properties to target diverse disease mechanisms.

As our understanding of molecular interactions continues to evolve through interdisciplinary approaches combining chemistry、biology、and computer science，compounds like 8，11-diazatricyclo4。3。3。0，1，6dodecane are poised to play a pivotal role in next-generation drug discovery programs。The integration of innovative synthetic methodologies with cutting-edge computational tools ensures that researchers can rapidly identify promising candidates while minimizing experimental trial-and-error。

In conclusion，the compound with CAS No．25682-47-7and product name 8，11-diazatricyclo4。3。3。0，1，6dodecane represents a significant advancement in pharmaceutical research due to its unique structural featuresand potential therapeutic applications．Further studies are warrantedto fully elucidate its pharmacological profileand explore its potential asa lead compoundfor drug development．With continued innovationin synthetic chemistryand computational biology，this classoftricyclicamineis likelyto make substantial contributions toimproving human health worldwide．

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)